Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Spontaneous Urticaria (CSU) Clear all
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Standard of Care
Biological · Other
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634
View directory record Official record
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 4 Interventional

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

NCT03183024
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
benralizumab, placebo
Biological
Lead sponsor
Jonathan A. Bernstein, MD
Other
Eligibility
19 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 28, 2026, 2:51 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Molecular Endotypes of Chronic Idiopathic Urticaria

NCT04774315
View directory record Official record
Conditions
Chronic Urticaria, Idiopathic
Interventions
Omalizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 28, 2026, 2:51 PM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), Placebo, LOU064 (open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
43
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Etanercept for the Treatment of Chronic Urticaria

NCT01030120
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
etanercept, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

NCT04109313
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
CDX-0159, Normal Saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 28, 2026, 2:51 PM EDT
Active, not recruiting No phase listed Observational

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
54
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

NCT01264939
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT05936567
View directory record Official record
Conditions
Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

NCT05795153
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
QGE031, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 28, 2026, 2:51 PM EDT
Terminated No phase listed Observational

The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism

NCT01008592
View directory record Official record
Conditions
Rhinitis, Urticaria
Interventions
levocetirizine or placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

NCT06577116
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
AK006 IV
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Birmingham, Alabama • Bakersfield, California • Upland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 28, 2026, 2:51 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

NCT05528861
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Lirentelimab (AK002), Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
51
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

NCT04180488
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Dupilumab SAR231893, Placebo, non sedating H1-antihistamine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 80 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

NCT05030311
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 28, 2026, 2:51 PM EDT
Recruiting Phase 2 Interventional

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

NCT06927999
View directory record Official record
Conditions
Urticaria Chronic
Interventions
Placebo, 0.5 mg epinephrine, 1 mg epinephrine
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glenview, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910
View directory record Official record
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

NCT04833855
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 28, 2026, 2:51 PM EDT
Recruiting Phase 2 Interventional

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651
View directory record Official record
Conditions
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
North Miami Beach, Florida • Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

NCT06873516
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
EVO756, Placebo control
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Fremont, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 28, 2026, 2:51 PM EDT